drugset / Trial / NCT04088864
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the safety and cancer killing ability of a cell therapy against a new cancer target (CD22).
Timeline
- Start
- 2020-01-10
- Primary completion
- 2021-11-08
- Completion
- 2022-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous CD22 CAR T | Cell therapy | 1e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 900 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |